JP2009518039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518039A5 JP2009518039A5 JP2008544528A JP2008544528A JP2009518039A5 JP 2009518039 A5 JP2009518039 A5 JP 2009518039A5 JP 2008544528 A JP2008544528 A JP 2008544528A JP 2008544528 A JP2008544528 A JP 2008544528A JP 2009518039 A5 JP2009518039 A5 JP 2009518039A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 16
- 102000038129 antigens Human genes 0.000 claims 16
- 108091007172 antigens Proteins 0.000 claims 16
- 102000004965 antibodies Human genes 0.000 claims 13
- 108090001123 antibodies Proteins 0.000 claims 13
- 102000005614 monoclonal antibodies Human genes 0.000 claims 7
- 108010045030 monoclonal antibodies Proteins 0.000 claims 7
- 102100004042 PTK7 Human genes 0.000 claims 6
- 101700007351 PTK7 Proteins 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 102000018748 Immunoconjugates Human genes 0.000 claims 2
- 108010027440 Immunoconjugates Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 210000004881 tumor cells Anatomy 0.000 claims 2
- 101700027111 3SA0 Proteins 0.000 claims 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000008383 Wilms Tumor Diseases 0.000 claims 1
- 101700067609 ctx Proteins 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (15)
- 単離されたヒトのモノクローナル抗体またはその抗原結合部分であって、該抗体が、
(a)ヒトのPTK7に結合し;かつ、
(b)ウィルムス腫瘍細胞株(ATCCアクセッション番号CRL−1441)に結合する、
抗体またはその抗原結合部分。 - 請求項1に記載の単離されたモノクローナル抗体またはその抗原結合部分であって、
(a)配列番号1〜4からなる群より選択されるアミノ酸配列を含む、重鎖可変領域;および、
(b)配列番号5〜10からなる群より選択されるアミノ酸配列を含む、軽鎖可変領域、
を含む、抗体またはその抗原結合部分。 - 単離されたモノクローナル抗体またはその抗原結合部分であって、
(a)配列番号1〜4からなる群より選択されるアミノ酸配列を含む、重鎖可変領域;および、
(b)配列番号5〜10からなる群より選択されるアミノ酸配列を含む、軽鎖可変領域、
を含み、ここで、該抗体またはその抗原結合部分はヒトのPTK7に結合する、抗体またはその抗原結合部分。 - ヒトのPTK7に結合する、単離されたモノクローナル抗体またはその抗原結合部分であって、
(a)配列番号11〜14からなる群より選択されるアミノ酸配列を含む重鎖可変領域CDR1;
(b)配列番号15〜18からなる群より選択されるアミノ酸配列を含む重鎖可変領域CDR2;
(c)配列番号19〜22からなる群より選択されるアミノ酸配列を含む重鎖可変領域CDR3;
(d)配列番号23〜28からなる群より選択されるアミノ酸配列を含む軽鎖可変領域CDR1;
(e)配列番号29〜34からなる群より選択されるアミノ酸配列を含む軽鎖可変領域CDR2;および、
(f)配列番号35〜40からなる群より選択されるアミノ酸配列を含む軽鎖可変領域CDR3
を含む、単離された抗体またはその抗原結合部分。 - モノクローナル抗体またはその抗原結合部分であって、
(a)配列番号4のアミノ酸配列を含む重鎖可変領域および/または配列番号10のアミノ酸配列を含む軽鎖可変領域;
(b)配列番号1のアミノ酸配列を含む重鎖可変領域および/または配列番号5のアミノ酸配列を含む軽鎖可変領域;
(c)配列番号1のアミノ酸配列を含む重鎖可変領域および/または配列番号6のアミノ酸配列を含む軽鎖可変領域;
(d)配列番号2のアミノ酸配列を含む重鎖可変領域および/または配列番号7のアミノ酸配列を含む軽鎖可変領域;
(e)配列番号3のアミノ酸配列を含む重鎖可変領域および/または配列番号8のアミノ酸配列を含む軽鎖可変領域;および、
(f)配列番号3のアミノ酸配列を含む重鎖可変領域および/または配列番号9のアミノ酸配列を含む軽鎖可変領域;
を含み、ここで、該抗体またはその抗原結合部分は、ヒトのPTK7に結合する、モノクローナル抗体またはその抗原結合部分。 - ヒトのPTK7への結合について請求項4に記載の抗体と競合する、単離されたモノクローナル抗体またはその抗原結合部分。
- 治療剤に結合している請求項1〜5のいずれか1項に記載の抗体またはその抗原結合部分を含む、免疫結合体。
- 前記治療剤が細胞毒素または放射性同位元素である、請求項7に記載の免疫結合体。
- 配列番号1、配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7、配列番号8、配列番号9または配列番号10を含む、抗体またはその抗原結合部分の可変領域をコードする、単離された核酸分子。
- 請求項9に記載の核酸分子を含む、発現ベクター。
- 請求項10に記載の発現ベクターを含む、宿主細胞。
- 抗PTK7抗体を調製するための方法であって、請求項11に記載の宿主細胞において該抗体を発現する工程、および、該宿主細胞から該抗体を単離する工程を含む、方法。
- ヒトのPTK7を発現する腫瘍細胞の増殖によって特徴づけられる疾患の治療または予防のための組成物であって、請求項1〜5のいずれか1項に記載の抗体またはその抗原結合部分を、該疾患を治療または予防するために有効な量において含む、組成物。
- 前記疾患が癌である、請求項13に記載の組成物。
- 前記癌が、結腸癌、肺癌、乳癌、すい臓癌、メラノーマ、急性骨髄性白血病、腎臓癌、膀胱癌、卵巣癌、および前立腺癌からなる群より選択される、請求項14に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74837305P | 2005-12-08 | 2005-12-08 | |
US60/748,373 | 2005-12-08 | ||
PCT/US2006/046837 WO2007067730A2 (en) | 2005-12-08 | 2006-12-08 | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009518039A JP2009518039A (ja) | 2009-05-07 |
JP2009518039A5 true JP2009518039A5 (ja) | 2010-02-04 |
JP5401639B2 JP5401639B2 (ja) | 2014-01-29 |
Family
ID=38123515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008544528A Expired - Fee Related JP5401639B2 (ja) | 2005-12-08 | 2006-12-08 | タンパク質チロシンキナーゼ7(ptk7)に対するヒトモノクローナル抗体およびそれらの使用 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8222375B2 (ja) |
EP (1) | EP1957539B1 (ja) |
JP (1) | JP5401639B2 (ja) |
KR (1) | KR101373464B1 (ja) |
CN (1) | CN101360761B (ja) |
AU (1) | AU2006321841C1 (ja) |
BR (1) | BRPI0619582A2 (ja) |
CA (1) | CA2632552C (ja) |
DK (1) | DK1957539T3 (ja) |
EA (1) | EA017812B1 (ja) |
ES (1) | ES2406063T3 (ja) |
HK (1) | HK1121174A1 (ja) |
IL (1) | IL191788A (ja) |
ME (1) | ME02002B (ja) |
NO (1) | NO20082559L (ja) |
NZ (2) | NZ569236A (ja) |
PL (1) | PL1957539T3 (ja) |
PT (1) | PT1957539E (ja) |
RS (1) | RS52804B (ja) |
SG (1) | SG177194A1 (ja) |
SI (1) | SI1957539T1 (ja) |
WO (1) | WO2007067730A2 (ja) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101373464B1 (ko) | 2005-12-08 | 2014-03-14 | 메다렉스, 엘.엘.시. | 단백질 티로신 키나제 7(ptk7)에 대한 인간 단일클론항체 및 그의 용도 |
AU2006321553B2 (en) * | 2005-12-08 | 2012-03-08 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to O8E |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
WO2009042209A2 (en) * | 2007-09-25 | 2009-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of thymically derived cd4 t cells by protein tyrosine kinase 7 expression |
AU2008323848B2 (en) * | 2007-11-07 | 2014-09-25 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
US20120027782A1 (en) * | 2007-11-30 | 2012-02-02 | Bristol-Myers Squibb Company | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) |
WO2009116764A2 (ko) * | 2008-03-17 | 2009-09-24 | 연세대학교 산학협력단 | Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제 |
KR101123130B1 (ko) * | 2008-03-17 | 2012-03-30 | 연세대학교 산학협력단 | Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제 |
CA2766747C (en) | 2009-07-10 | 2019-04-02 | Innate Pharma | Tlr3 binding agents |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
ES2650630T3 (es) | 2011-10-03 | 2018-01-19 | The University Of North Carolina At Chapel Hill | Compuestos de pirrolopirimidina para el tratamiento del cáncer |
SI2814829T1 (sl) | 2012-02-13 | 2017-02-28 | Bristol-Myers Squibb Company | Spojine enediyna, njegovi konjugati in uporaba in postopki |
EP2852579A4 (en) | 2012-05-22 | 2015-12-30 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER |
CN104379603B (zh) | 2012-05-31 | 2017-11-07 | 先天制药公司 | Tlr3结合剂 |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
KR102215954B1 (ko) | 2013-02-14 | 2021-02-15 | 브리스톨-마이어스 스큅 컴퍼니 | 튜부리신 화합물, 그의 제조 및 사용 방법 |
US9777013B2 (en) | 2013-08-14 | 2017-10-03 | William Marsh Rice University | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
WO2015157128A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
DK3137114T3 (da) * | 2014-04-30 | 2021-01-25 | Pfizer | Anti-PTK7-antistof-lægemiddelkonjugater |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
SI3221346T1 (sl) | 2014-11-21 | 2020-11-30 | Bristol-Myers Squibb Company | Protitelesa vsebujoča modificirana težko konstantna območja |
JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
HRP20230060T1 (hr) | 2015-05-29 | 2023-03-17 | Bristol-Myers Squibb Company | Antitijela protiv ox40 i njihova primjena |
CN108431034A (zh) | 2015-12-21 | 2018-08-21 | 百时美施贵宝公司 | 用于位点-特异性缀合的变体抗体 |
KR20180104036A (ko) | 2016-01-22 | 2018-09-19 | 머크 샤프 앤드 돔 코포레이션 | 항-응고 인자 xi 항체 |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
KR20190005924A (ko) | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체 |
SG10202103120UA (en) | 2016-06-14 | 2021-05-28 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
CN109641911B (zh) | 2016-08-19 | 2023-02-21 | 百时美施贵宝公司 | seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法 |
US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
SG10201913206RA (en) | 2017-05-25 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
BR112020024022A2 (pt) | 2018-05-29 | 2021-02-23 | Bristol-Myers Squibb Company | porções autoimolantes modificadas para uso em profármacos e conjugados e métodos de uso e preparação |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
MX2021005400A (es) * | 2018-11-07 | 2021-07-06 | Crispr Therapeutics Ag | Terapia del cancer con celulas inmunitarias anti-ptk7. |
US20220106400A1 (en) | 2018-11-28 | 2022-04-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
KR20210098488A (ko) | 2018-11-30 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 |
US20220031860A1 (en) | 2018-12-12 | 2022-02-03 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
KR102236127B1 (ko) * | 2019-08-08 | 2021-04-07 | 주식회사 하울바이오 | 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도 |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
AR122014A1 (es) * | 2020-05-06 | 2022-08-03 | Crispr Therapeutics Ag | Receptor de antígenos quimérico enmascarado específico para la proteína tirosina cinasa de tipo 7 (ptk7) y células inmunitarias que expresan el mismo |
WO2022015113A1 (ko) * | 2020-07-16 | 2022-01-20 | 연세대학교 산학협력단 | Ptk7에 특이적으로 결합하는 항체 및 이의 용도 |
CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
CN114213541B (zh) * | 2021-12-20 | 2022-12-30 | 南京诺唯赞生物科技股份有限公司 | 一种全能核酸酶的单克隆抗体及其制备方法 |
WO2023180484A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing ptk7 |
WO2023225639A1 (en) * | 2022-05-19 | 2023-11-23 | Mythic Therapeutics, Inc. | Ptk7-binding proteins with ph-dependent binding and uses thereof |
GB202209196D0 (en) * | 2022-06-22 | 2022-08-10 | Almac Discovery Ltd | Bi-specific antigen binding molecules |
WO2024037621A1 (en) * | 2022-08-19 | 2024-02-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Ptk7-binding protein and use thereof |
WO2024054030A1 (ko) * | 2022-09-06 | 2024-03-14 | 연세대학교 산학협력단 | 항-ptk7 항체 및 이의 용도 |
WO2024080325A1 (ja) * | 2022-10-14 | 2024-04-18 | Jsr株式会社 | 抗体及びその使用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708930A (en) * | 1984-11-09 | 1987-11-24 | Coulter Corporation | Monoclonal antibody to a human carcinoma tumor associated antigen |
AU6238696A (en) * | 1995-05-25 | 1996-12-11 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders |
WO1997012862A1 (en) | 1995-10-03 | 1997-04-10 | The Scripps Research Institute | Cbi analogs of cc-1065 and the duocarmycins |
WO1998045708A1 (en) | 1997-04-08 | 1998-10-15 | Sugen, Inc. | Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases |
JP2002503228A (ja) | 1997-05-22 | 2002-01-29 | ザ スクリップス リサーチ インスティテュート | デュオカルマイシンおよびcc−1065の類似体 |
JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | HER2/neuに対するヒトモノクローナル抗体 |
CA2440703A1 (en) | 2001-01-24 | 2002-08-01 | Protein Design Labs, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
JP2005527180A (ja) | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス, インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
GB0114033D0 (en) | 2001-06-09 | 2001-08-01 | Innovata Biomed Ltd | Process |
DE60239679D1 (de) | 2001-06-11 | 2011-05-19 | Medarex Inc | Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen |
KR20090125840A (ko) | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체 |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
CA2459308A1 (en) | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
JP2003088388A (ja) * | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長cDNA |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
JP4353799B2 (ja) * | 2001-10-09 | 2009-10-28 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | 転移に関連するホスファターゼ |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
ES2427964T3 (es) * | 2002-01-18 | 2013-11-05 | Pierre Fabre Medicament | Nuevos anticuerpos anti-IGF-IR y sus aplicaciones |
US20040197792A1 (en) * | 2002-07-15 | 2004-10-07 | Sugen, Inc. | Novel Kinases |
GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
ATE488588T1 (de) * | 2003-03-10 | 2010-12-15 | Japan Science & Tech Agency | Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker |
EP1639090A4 (en) * | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER |
WO2005063987A1 (en) | 2003-12-19 | 2005-07-14 | Aveo Pharmaceuticals, Inc. | Gp153: methods and compositions for treating cancer |
CA2564092A1 (en) | 2004-04-29 | 2005-12-15 | Genzyme Corporation | Methods and compositions for the treatment of polycystic diseases |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
CA2564076C (en) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
JP2008504270A (ja) * | 2004-06-23 | 2008-02-14 | ジェンザイム・コーポレイション | 嚢胞性疾患を処置するための方法および組成物 |
WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
JP5290756B2 (ja) | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
KR101373464B1 (ko) | 2005-12-08 | 2014-03-14 | 메다렉스, 엘.엘.시. | 단백질 티로신 키나제 7(ptk7)에 대한 인간 단일클론항체 및 그의 용도 |
US20120027782A1 (en) | 2007-11-30 | 2012-02-02 | Bristol-Myers Squibb Company | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
-
2006
- 2006-12-08 KR KR1020087015763A patent/KR101373464B1/ko active IP Right Grant
- 2006-12-08 SG SG2011090792A patent/SG177194A1/en unknown
- 2006-12-08 PT PT68485085T patent/PT1957539E/pt unknown
- 2006-12-08 DK DK06848508.5T patent/DK1957539T3/da active
- 2006-12-08 US US12/095,986 patent/US8222375B2/en active Active
- 2006-12-08 CN CN2006800510578A patent/CN101360761B/zh not_active Expired - Fee Related
- 2006-12-08 NZ NZ569236A patent/NZ569236A/en not_active IP Right Cessation
- 2006-12-08 EP EP06848508.5A patent/EP1957539B1/en not_active Revoked
- 2006-12-08 SI SI200631569T patent/SI1957539T1/sl unknown
- 2006-12-08 RS RS20130230A patent/RS52804B/en unknown
- 2006-12-08 WO PCT/US2006/046837 patent/WO2007067730A2/en active Application Filing
- 2006-12-08 ES ES06848508T patent/ES2406063T3/es active Active
- 2006-12-08 JP JP2008544528A patent/JP5401639B2/ja not_active Expired - Fee Related
- 2006-12-08 PL PL06848508T patent/PL1957539T3/pl unknown
- 2006-12-08 EA EA200801509A patent/EA017812B1/ru not_active IP Right Cessation
- 2006-12-08 CA CA2632552A patent/CA2632552C/en not_active Expired - Fee Related
- 2006-12-08 BR BRPI0619582-2A patent/BRPI0619582A2/pt not_active Application Discontinuation
- 2006-12-08 AU AU2006321841A patent/AU2006321841C1/en not_active Ceased
- 2006-12-08 ME MEP-2013-230A patent/ME02002B/me unknown
- 2006-12-08 NZ NZ594466A patent/NZ594466A/xx not_active IP Right Cessation
-
2008
- 2008-05-28 IL IL191788A patent/IL191788A/en not_active IP Right Cessation
- 2008-06-02 NO NO20082559A patent/NO20082559L/no not_active Application Discontinuation
-
2009
- 2009-02-10 HK HK09101212.1A patent/HK1121174A1/xx not_active IP Right Cessation
-
2012
- 2012-04-09 US US13/442,499 patent/US9505845B2/en active Active
- 2012-05-10 US US13/468,624 patent/US9102738B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009518039A5 (ja) | ||
JP2022093564A5 (ja) | ||
HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
JP2020501531A5 (ja) | ||
JP2011505146A5 (ja) | ||
HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
JP2010511388A5 (ja) | ||
JP2019535670A5 (ja) | ||
JP2020510653A5 (ja) | Ceaを標的にする多重特異性結合タンパク質 | |
JP2014039548A5 (ja) | ||
RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
JP2010533498A5 (ja) | ||
JP2009545325A5 (ja) | ||
JP2014518615A5 (ja) | ||
JP2006502699A5 (ja) | ||
JP2013527761A5 (ja) | ||
HRP20171274T1 (hr) | U potpunosti ljudska antitijela specifična za cadm1 | |
JP2010535713A5 (ja) | ||
WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
JP2012523848A5 (ja) | ||
CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
JP2020502271A5 (ja) | ||
CN108383909A (zh) | 抗sez6抗体及使用方法 | |
WO2006099875A8 (en) | Antibodies against cd38 for treatment of multiple myeloma |